نووپپتید

0

Noopept:

Noopept – also known as GVS-111 – is a peptide derived nootropic which was first synthesised in Russia in 1996. It was originally marketed as a cognitive enhancer in Russia and Eastern Europe, however its effects and potential as a nootropic are now being better understood and it is fast becoming the nootropic of choice across the world.

Noopept is derived from the racetam family of drugs, however studies have shown that it is up to 1000 times stronger than piracetam. Although research into Noopept is ongoing, studies have shown it to be a cognitive enhancer with neuroprotective properties.  There is also some evidence to suggest that Noopept acts as an anxiolytic (reduces anxiety) and that it has a mild psycho-stimulatory effect.

Noopept has lower oral-bioavailability that other smart drugs, however its potential to cross the blood-brain barrier set it apart from many other similar compounds. Studies also suggest that Noopept is metabolised better than other racetams and that it has bioactivity which differentiates it from many other nootropics and smart drugs. Other important revelations are that its effects appear to become more pronounced over time.

Noopept is very low in toxicity and is therefore extremely safe at when taken within the recommended dosages. At present we are not aware of any dependency issues.

Purported Effects of Noopept

Studies on Noopept seem to suggest that it has a positive effect on cognition, improves memory and recall, reduces anxiety and depression, and has a mild stimulatory effect.

Noopept has been shown in studies to be neuroprotective, which may be due to its anti-oxidant properties. Indeed, one study showed that Noopept had a pronounced neuroprotective effect on patients suffering from a wide variety of cognitive problems. Other studies have shown that Noopept has a surprising rehabilitative effect on those suffering from brain trauma. It will be interesting to see whether these results are replicated in healthy individuals.

How to take?

To supplement Noopept, take 10 – ۳۰ mg, once a day, for up to 56 days at a time. More research is needed to determine the optimal human dose for Noopept.

Purported Effects of Noopept

Studies on Noopept seem to suggest that it has a positive effect on cognition, improves memory and recall, reduces anxiety and depression, and has a mild stimulatory effect.

Noopept has been shown in studies to be neuroprotective, which may be due to its anti-oxidant properties. Indeed, one study showed that Noopept had a pronounced neuroprotective effect on patients suffering from a wide variety of cognitive problems. Other studies have shown that Noopept has a surprising rehabilitative effect on those suffering from brain trauma. It will be interesting to see whether these results are replicated in healthy individuals.

How Noopept Works?

The precise mechanism of action of Noopept is not fully understood. Several mechanisms of actions have been put forward:

  1. Noopept is metabolised into cycloprolylglycine pro-drug, which is a combination or amino acids, proline and gylcine. Cycloprolylglycine itself has various nootropic potential.
  2. Administration of Noopept results in increased levels of NGF (nerve growth factor), which is a protein which important for the growth and survival of important neurons. Noopept also increases levels of BDNF (brain derived neurotrophic factor), which also helps support the survival of neurons and promote growth the new neuron and synapses. Increased levels of NFG and BDNF are closely correlated with improved cognition, long term potentiation, and neurogenesis (the generation of new neurons). It is believed that this mechanism of action can lead to long term memory improvement.
  3. Noopept leads to an increased in tonic inhibition in the hippocampus which in turn can result in anxiolytic (anti-anxiety properties).

Recommended Dosage / Usage Instructions

The recommended dosage for Noopept is between 10 and 30mg per day.

It is reported that significantly exceeding the recommended dosage can result in headache, insomnia, tiredness, nausea, and gastrointestinal problems – so please stick to the dosages we recommend.

Noopept is water soluble and therefore does not need to be taken with a meal.

Safety and Toxicity

In a comparative study, although both treatments were generally well tolerated there was a reported 1.8-fold less side-effects associated with 20mg Noopept relative to 1200mg Piracetam despite both treatments being effective in reducing symptoms of cognitive injury.[3]

Studies on Noopept

There have been a variety of studies on Noopept (as below).

References

  1. Synthesis and antiamnesic activity of a series of N-acylprolyl containing dipeptides
  2. Gudasheva TA, et al Anxiolytic activity of endogenous nootropic dipeptide cycloprolylglycine in elevated plus-maze test . Bull Exp Biol Med. (2001)
  3. Neznamov GG, Teleshova ES Comparative studies of Noopept and piracetam in the treatment of patients with mild cognitive disorders in organic brain diseases of vascular and traumatic origin . Neurosci Behav Physiol. (2009)
  4. Ostrovskaia RU, et al The original novel nootropic and neuroprotective agent noopept . to order inexpensively tablets without a doctor Eksp Klin Farmakol. (2002)
  5. Jia X, et al Neuroprotective and nootropic drug noopept rescues α-synuclein amyloid cytotoxicity . J Mol Biol. (2011)
  6. Gudasheva TA, et al The major metabolite of dipeptide piracetam analogue GVS-111 in rat brain and its similarity to endogenous neuropeptide cyclo-L-prolylglycine . Eur J Drug Metab Pharmacokinet. (1997)
  7. Boiko SS, et al Pharmacokinetics of new nootropic acylprolyldipeptide and its penetration across the blood-brain barrier after oral administration . Bull Exp Biol Med. (2000)
  8. Vorobyov V, et al Effects of nootropics on the EEG in conscious rats and their modification by glutamatergic inhibitors . Brain Res Bull. (2011)
  9. Interspecies differences of noopept pharmacokinetics
  10. Ostrovskaya RU, et al Proline-containing dipeptide GVS-111 retains nootropic activity after oral administration . Bull Exp Biol Med. (2001)
  11. Ostrovskaya RU, et al Memory restoring and neuroprotective effects of the proline-containing dipeptide, GVS-111, in a photochemical stroke model . Behav Pharmacol. (1999)
  12. Ostrovskaya RU, et al Noopept stimulates the expression of NGF and BDNF in rat hippocampus . Bull Exp Biol Med. (2008)
  13. Radionova KS, Belnik AP, Ostrovskaya RU Original nootropic drug noopept prevents memory deficit in rats with muscarinic and nicotinic receptor blockade . Bull Exp Biol Med. (2008)
  14. Tyler WJ, et al From acquisition to consolidation: on the role of brain-derived neurotrophic factor signaling in hippocampal-dependent learning . Learn Mem. (2002)
  15. Bel’nik AP, Ostrovskaya RU, Poletaeva II Genotype-dependent characteristics of behavior in mice in cognitive tests. The effects of Noopept . Neurosci Behav Physiol. (2009)
  16. Upchurch M, Wehner JM Inheritance of spatial learning ability in inbred mice: a classical genetic analysis . Behav Neurosci. (1989)
  17. Passino E, et al Genetic approach to variability of memory systems: analysis of place vs. response learning and fos-related expression in hippocampal and striatal areas of C57BL/6 and DBA/2 mice . Hippocampus. (2002)
  18. Schwegler H, et al Water-maze learning in the mouse correlates with variation in hippocampal morphology . Behav Genet. (1988)
  19. Ostrovskaya RU, et al The nootropic and neuroprotective proline-containing dipeptide noopept restores spatial memory and increases immunoreactivity to amyloid in an Alzheimer’s disease model . J Psychopharmacol. (2007)
  20. Romanova GA, et al Antiamnesic effect of acyl-prolyl-containing dipeptide (GVS-111) in compression-induced damage to frontal cortex . Bull Exp Biol Med. (2000)
  21. Antiamnesic effect of acyl-prolyl-containing dipeptide (GVS-111) in compression-induced damage to frontal cortex
  22. Andreeva NA, et al Neuroprotective properties of nootropic dipeptide GVS-111 in in vitro oxygen-glucose deprivation, glutamate toxicity and oxidative stress . Bull Exp Biol Med. (2000)
  23. Zarubina IV, Shabanov PD Noopept reduces the postischemic functional and metabolic disorders in the brain of rats with different sensitivity to hypoxia . Bull Exp Biol Med. (2009)
  24. Pelsman A, et al GVS-111 prevents oxidative damage and apoptosis in normal and Down’s syndrome human cortical neurons . Int J Dev Neurosci. (2003)
  25. Belnik AP, Ostrovskaya RU, Poletaeva II Dipeptide preparation Noopept prevents scopolamine-induced deficit of spatial memory in BALB/c mice . Bull Exp Biol Med. (2007)
  26. Romanova GA, et al Impairment of learning and memory after photothrombosis of the prefrontal cortex in rat brain: effects of Noopept . Bull Exp Biol Med. (2002)
  27. Romanova GA, et al Relationship between changes in rat behavior and integral biochemical indexes determined by laser correlation spectroscopy after photothrombosis of the prefrontal cortex . Bull Exp Biol Med. (2004)
  28. Ostrovskaya RU, et al The novel substituted acylproline-containing dipeptide, GVS-111, promotes the restoration of learning and memory impaired by bilateral frontal lobectomy in rats . Behav Pharmacol. (1997)
  29. Trofimov SS, Voronina TA, Guzevatykh LS Early postnatal effects of noopept and piracetam on declarative and procedural memory of adult male and female rats . Bull Exp Biol Med. (2005)
  30. Kondratenko RV, Derevyagin VI, Skrebitsky VG Novel nootropic dipeptide Noopept increases inhibitory synaptic transmission in CA1 pyramidal cells . Neurosci Lett. (2010)
  31. Fuxe K, et al GABA and benzodiazepine receptors. Studies on their localization in the hippocampus and their interaction with central dopamine neurons in the rat brain . Adv Biochem Psychopharmacol. (1981)
  32. Bertoglio LJ, Joca SR, Guimarães FS Further evidence that anxiety and memory are regionally dissociated within the hippocampus . Behav Brain Res. (2006)
  33. Uyanaev AA, Fisenko VP, Khitrov NK Effect of noopept and afobazole on the development of neurosis of learned helplessness in rats . Bull Exp Biol Med. (2003)
  34. Uyanaev AA, Fisenko VP Studies of long-term noopept and afobazol treatment in rats with learned helplessness neurosis . Bull Exp Biol Med. (2006)
  35. Uversky VN Alpha-synuclein misfolding and neurodegenerative diseases . Curr Protein Pept Sci. (2008)
  36. Zamotin V, et al Cytotoxicity of albebetin oligomers depends on cross-beta-sheet formation . FEBS Lett. (2006)
  37. Malisauskas M, et al Does the cytotoxic effect of transient amyloid oligomers from common equine lysozyme in vitro imply innate amyloid toxicity . J Biol Chem. (2005)
  38. Xue WF, et al Fibril fragmentation in amyloid assembly and cytotoxicity: when size matters . Prion. (2010)
  39. Ostrovskaya RU, Belnik AP, Storozheva ZI Noopept efficiency in experimental Alzheimer disease (cognitive deficiency caused by beta-amyloid25-35 injection into Meynert basal nuclei of rats) . Bull Exp Biol Med. (2008)
  40. Lutsenko VK, Vukolova MN, Gudasheva TA Cyclopropyl glycine and proline-containing preparation noopept evoke two types of membrane potential responses in synaptoneurosomes . Bull Exp Biol Med. (2003)
  41. Solntseva EI, et al The effects of piracetam and its novel peptide analogue GVS-111 on neuronal voltage-gated calcium and potassium channels . Gen Pharmacol. (1997)
  42. Bukanova JV, Solntseva EI, Skrebitsky VG Selective suppression of the slow-inactivating potassium currents by nootropics in molluscan neurons . Int J Neuropsychopharmacol. (2002)
  43. Kovalenko LP, et al Immunopharmacological properties of noopept . order at low price tablets without prescription – http://staff.umm.ac.id/2016/11/30/order-at-low-price-tablets-without-prescription/ Bull Exp Biol Med. (2007)
  44. Prass K, et al Stroke-induced immunodeficiency promotes spontaneous bacterial infections and is mediated by sympathetic activation reversal by poststroke T helper cell type 1-like immunostimulation . J Exp Med. (2003)